Danicopan

Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) [1].

Product Specifications

CAS Number

[1903768-17-1]

Product Name Alternative

ACH-4471

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Complement System

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/danicopan.html

Purity

99.91

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C([C@H]1N(C(CN2N=C(C(C)=O)C3=C2C=CC(C4=CN=C(C)N=C4)=C3)=O)C[C@H](F)C1)NC5=NC(Br)=CC=C5

Molecular Formula

C26H23BrFN7O3

Molecular Weight

580.41

Precautions

H302, H315, H319, H335

References & Citations

[1]Yuan X, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017 Mar;102 (3) :466-475.|[2]Boyer DD, Ko YP, Podos SD, et al. Danicopan, an Oral Complement Factor D Inhibitor, Exhibits High and Sustained Exposure in Ocular Tissues in Preclinical Studies. Transl Vis Sci Technol. 2022;11 (10) :37.